Lipids in Medical Technology

Video: New Dove(R) Body Washes with NutriumMoisture(TM) Restore Skin's Natural Moisture

... Current body washes actually damage proteins and lipids in the skin's outer layer, often leading to the loss of critical moisture. Recognizing skin lipids require different care than skin proteins, Dove ... to preserve both skin's natural proteins and lipids while significantly reducing dryness and ...

Abbott's Phase III Studies of Investigational TriLipix(TM) (ABT-335), in Combination With Statins, Meets Primary Endpoints on Improving LDL, Triglycerides and HDL

... Combination With Statins Improved All Three Key lipids and Had Reported Safety Consistent With ... significantly improved three key lipids -- LDL "bad" cholesterol, triglycerides and HDL ... or simvastatin improved all three key lipids -- LDL, HDL and triglycerides -- in patients with ...

Novel PCT Method Unveiled by Pressure BioSciences, Inc. and Collaborators at the Harvard School of Public Health

... of nucleic acids (DNA and RNA), proteins, and lipids from animal and plant samples routinely used in ... is the study of nucleic acids, proteins, and lipids from the same research sample. Unfortunately, ... ability to simultaneously extract DNA, RNA, and lipids together with proteins from the same initial ...

New Analysis Shows Troubling Trend in Triglyceride Levels May Be Linked to Rising Rates of Obesity

... preventive care. Patients, for their part, should be aware of all three lipids and work with their healthcare professionals to reach optimal lipid ... related to dyslipidemias. To help consumers better understand and manage lipids the NLA launched the http://www.learnyourlipids.com Web site. ...

Olanzapine Long-Acting Injection (LAI) Shown to Maintain Treatment Benefit in Schizophrenia for up to Six Months

... which regular glucose control is recommended. Undesirable alterations in lipids have been observed in olanzapine-treated patients in placebo-controlled ... patients and in patients with risk factors for the development of lipids disorders. The proportion of patients who had adverse, clinically ...

Surface Logix Presents Positive Phase 1 Repeat-Dose Trial Data on SLx-4090 at The 16th International Symposium on Drugs Affecting Lipid Metabolism

... being developed for the treatment of dyslipidemia (abnormal levels of lipids in the bloodstream). The data indicated not only that repeat- dosing at ... being developed for the treatment of dyslipidemia (abnormal levels of lipids in the bloodstream). Surface Logix designed SLx-4090 using its proprietary ...

Lpath Demonstrates Preclinical Efficacy of Lpathomab(TM) and Initiates Humanization Process

... an emerging field of medical science whereby bioactive signaling lipids are targeted for treating important human diseases. ASONEP(TM) (the ... company's unique ability to generate novel antibodies against bioactive lipids is based on its ImmuneY2(TM) drug-discovery engine, which the company is ...

Cleveland Clinic Researchers Identify Mechanism Behind Platelet Function and Potentially Fatal Blood Clot Formation

... a condition in which there are abnormal levels of cholesterol or other lipids in the blood. It has long been recognized that high fat diet and abnormal ... modulates platelet activity in response to oxidant stress and abnormal lipids in the blood. The researchers demonstrated that platelets from humans ...

TWO NEW KLRI PEER-REVIEWED PUBLICATIONS: Hormone Therapy May Reduce Atherosclerosis in Women Close to Menopause; Growth Hormone May Increase Risk of Diabetes, Improve Lipid Profile in Men

... that GH caused insulin resistance (the body's inability to respond to and use the insulin it produces) to increase, yet it had a beneficial effect on lipids (molecules in the blood that include cholesterol and triglycerides). "It's extremely unusual to analyze the effect of both growth hormone and ...

Transave Receives $2.2 Million Cystic Fibrosis Foundation Award for Development of ARIKACE(TM)

... pulmonary liposome technology prolongs the release of amikacin in the lungs while minimizing systemic exposure. The treatment uses biocompatible lipids endogenous to the lung that are formulated into small (0.3 micron), neutral liposomes that enable penetration of the biofilm and are highly ...

FDA Advisory Committee Votes in Favor of Zyprexa for Two Adolescent Indications

... Patients who develop symptoms of hyperglycemia during treatment should undergo fasting blood glucose testing. Undesirable alterations in lipids have been observed with Zyprexa use. Clinical monitoring, including baseline and follow-up lipid evaluations in patients using Zyprexa, is advised. ...

Data Demonstrated ACTEMRA(R) (tocilizumab) Significantly Inhibited Progression of Structural Joint Damage in Rheumatoid Arthritis Patients

... in patients; these increases were generally mild and reversible, with no evidence of hepatic injuries. Laboratory changes, including increases in lipids (total cholesterol, LDL, HDL, triglycerides) and decreases in neutrophils and platelets, were seen in patients without association with clinical ...

Isis Highlights New Data on Antisense Drugs to Treat Type 2 Diabetes and Obesity at ADA Scientific Sessions

... Booten, B.P. Monia, S. Bhanot. Antisense Inhibition of cAMP Response Element Binding Protein (CREB) Expression Lowers Plasma Glucose and lipids in Diabetic Rodents (Oral Presentation) Authors: S.F. Murray, S.L. Booten, L.M. Watts, B.P. Monia, S. Bhanot. A Newly Identified Role of ...

Afinitor(R) Phase II Data Show Positive Results for Patients With Multiple Types of Lymphoma, Leading to Phase III Trial

... invasive fungal infections should not receive Afinitor. Oral ulceration is a common side effect with Afinitor. Renal function, blood glucose, lipids and hematological parameters should be evaluated prior to the start of therapy with Afinitor and periodically thereafter. Strong or moderate CYP3A4 ...

Video: Data on More Than 15 Novartis Oncology Compounds at ASCO Highlight Progress Toward Targeted Therapies for Diverse Tumor Types

... invasive fungal infections should not receive Afinitor. Oral ulceration is a common side effect with Afinitor. Renal function, blood glucose, lipids and hematological parameters should be evaluated prior to the start of therapy with Afinitor and periodically thereafter. Strong or moderate CYP3A4 ...

Two-Year Data Reinforce Effect of ACTEMRA(R) (tocilizumab) in Inhibiting Progression of Joint Damage and Improving Physical Function in Rheumatoid Arthritis Patients

... in patients; these increases were generally mild and reversible, with no evidence of hepatic injuries. Laboratory changes, including increases in lipids (total cholesterol, LDL, HDL, triglycerides) and decreases in neutrophils and platelets, were seen in patients without association with clinical ...

Video: Afinitor(R) Approved in US as First Treatment for Patients With Advanced Kidney Cancer After Failure of Either Sunitinib or Sorafenib

... invasive fungal infections should not receive Afinitor. Oral ulceration is a common side effect with Afinitor. Renal function, blood glucose, lipids and hematological parameters should be evaluated prior to the start of therapy with Afinitor and periodically thereafter. Strong or moderate CYP3A4 ...

Lake Hospital System Receives $60,000 Grant for Groundbreaking Music Therapy Study

... diet, exercise and insulin. "We've known for many years that patients who effectively learn to control blood glucose, blood pressure and blood lipids have decreased occurrence of serious complications, including cardiovascular disease, kidney damage, blindness and lower limb amputations," explained ...

Emerging Therapies Could Help Ease The Chronic Symptoms of Atopic Dermatitis For Adults and Children

... are designed to improve the barrier function of the skin that is compromised in atopic dermatitis. They work by adding lipids, ceramides (natural lipids that act as water regulators) or other agents that help to make damaged skin more "normal." These topical preparations include water-based emulsion ...

FDA Issues a Complete Response Letter for Lilly's Olanzapine LAI for Treatment of Schizophrenia in Adults

... Patients who develop symptoms of hyperglycemia during treatment should undergo fasting blood glucose testing. Undesirable alterations in lipids have been observed with olanzapine use. Clinical monitoring, including baseline and follow-up lipid evaluations in patients using olanzapine, is ...

Synvista Therapeutics Announces First Dosing of SYI-2074 in Clinical Trial for Psoriasis

... In humans, research suggests the risk of cardiovascular disease varies inversely with levels of GPx activity (i.e., higher levels of oxidized lipids promote the creation of oxygen free radicals and reactive oxygen species (ROS), such as H2O2, which can promote inflammation). As noted ...

Roche and FDA Agree on Pathway Towards U.S. Approval of ACTEMRA(R) (tocilizumab)

... in patients; these increases were generally mild and reversible, with no evidence of hepatic injuries. Laboratory changes, including increases in lipids (total cholesterol, LDL, HDL, triglycerides) and decreases in neutrophils and platelets, were seen in patients without association with clinical ...

March of Dimes Honors Dr. Susan Carlson for Outstanding Work In Maternal-Fetal Nutrition

... is an author of numerous peer-reviewed articles and textbook chapters. She reviews widely for journals devoted to publishing research in pediatrics, lipids and nutrition. She is a member of the American Society for Nutrition and the American Pediatric Society. The March of Dimes is the leading ...

New Study Demonstrated ACTEMRA(R) (tocilizumab) Inhibited Progression of Joint Damage in Rheumatoid Arthritis Patients

... in patients; these increases were generally mild and reversible, with no evidence of hepatic injuries. Laboratory changes, including increases in lipids (total cholesterol, LDL, HDL, triglycerides) and decreases in neutrophils and platelets, were seen in patients without association with ...

ACTEMRA (R) (tocilizumab) Significantly Reduced Signs and Symptoms of Rheumatoid Arthritis in Patients Who Failed Prior Treatments

... in patients; these increases were generally mild and reversible, with no evidence of hepatic injuries. Laboratory changes, including increases in lipids (total cholesterol, LDL, HDL, triglycerides) and decreases in neutrophils and platelets, were seen in patients without association with ...

Nature Publication Reports on Key Role of Bile Acids in Glucose Metabolism and Insulin Signaling

... YORK, Aug. 7 /PRNewswire/ -- Historically, bile acids have been recognized primarily as natural detergents that regulate the absorption of dietary lipids and cholesterol homeostasis. However, recent research advances provide evidence that bile acids have broader systemic endocrine functions, acting as ...

Genzyme and Isis Begin Second Phase 3 Trial Of Mipomersen

... of "bad" cholesterol. In phase 2 studies, mipomersen, a weekly injectable therapeutic, was observed to reduce cholesterol and other atherogenic lipids beyond reductions achieved with standard lipid-lowering drugs, enabling more patients to achieve LDL-C targets. In 2008 Genzyme and Isis completed ...

Olanzapine Long-Acting Injection (LAI) Data Presented at First Annual Schizophrenia International Research Society Conference

... testing. Patients who develop symptoms of hyperglycemia during treatment should undergo fasting blood glucose testing. Undesirable alterations in lipids have been observed with olanzapine use. Clinical monitoring, including baseline and follow-up lipid evaluations in patients using olanzapine, is ...

Pilot Therapeutics Announces Relaunch as Gene Smart(TM) Health

... at Wake Forest University School of Medicine. Dr. Chilton is also director of the Wake Forest and Brigham and Women's Center for Botanical lipids which is supported by a grant from the National Center for Complementary and Alternative Medicine and the Office of Dietary Supplements. ...

Transave Announces Positive Phase II Results for Once-Daily Arikace(TM) in the Treatment of Cystic Fibrosis Patients Who Have Pseudomonas Lung Infections

... co-lead investigator of the study. Arikace is a novel molecular entity comprised of the antibiotic amikacin, which is enclosed in nanocapsules of lipids called liposomes. Arikace was administered once daily for 28 days at 280 mg and 560 mg dosages, using a novel inhalation device, the eFlow(R) ...

Abbott's Phase III Sub-Group Analysis Shows Investigational TriLipix(TM) in Combination with CRESTOR(R) Improves Key Lipids in Patients with Mixed Dyslipidemia and Type 2 Diabetes

... commonly characterized by high triglycerides, low HDL and moderately high LDL. "Treatment guidelines recommend aggressive treatment of lipids in patients with mixed dyslipidemia and type 2 diabetes," said Peter H. Jones, M.D., FACP, Methodist DeBakey Heart and Vascular Center, Houston, and ...

Synvista Therapeutics Reports Results of Three Phase 2 Clinical Trials of SYI-2074 in Diabetic Patients with Cardiovascular Disease

... 453 ng/mg Cr (p=0.001). Trial 201 showed that SYI-2074, in Hp2-2 diabetic patients, did not demonstrate a dose-related improvement in all oxidized lipids and all markers of oxidative stress after one month. In Trial 203, SYI-2074 did not provide evidence of protection against cardiac injury in diabetic ...

Phase III Study of Abbott's Investigational TriLipix(TM) in Combination With AstraZeneca's CRESTOR(R) Meets Primary Endpoints on Key Lipids

... with AstraZeneca's CRESTOR(R) (rosuvastatin calcium) led to greater improvements than the corresponding monotherapy in treating all three key lipids -- LDL "bad" cholesterol, HDL "good" cholesterol and triglycerides. Results from this Phase III study were presented today at the National Lipid ...

New Analyses Presented at ASCO Reaffirmed Efficacy and Safety of TORISEL in Patients With Advanced Kidney Cancer

... pivotal phase 3 study of TORISEL for advanced RCC, including high levels of blood glucose (hyperglycemia), cholesterol (hypercholesterolemia), and lipids (hyperlipidemia). More patients treated with TORISEL, either with or without diabetes, developed hyperglycemia of grade 2 or higher (P=0.002 for ...

Isis Reports Reduction of apoB-100 Levels in a Murine Model Resulting in Up to 92% Reduction of Atherosclerosis

... disease. Currently in Phase 3 development, mipomersen has been shown in Phase 2 trials to reduce cholesterol and other atherogenic lipids more than 40 percent beyond reductions achieved with standard lipid-lowering drugs, enabling more patients to achieve LDL-C targets. These trials ...

Update From Mipomersen Extended Dosing Study Continues to Show That Mipomersen Is Well Tolerated and Maintains Activity in Patients Treated for Up to 16 Months

... cardiovascular disease. Currently in Phase 3 development, mipomersen has been shown in Phase 2 trials to reduce cholesterol and other atherogenic lipids more than 40 percent beyond reductions achieved with standard lipid-lowering drugs, enabling more patients to achieve LDL-cholesterol targets. These ...

Reduced Lung Capacity Accelerates With Diabetes

... from the American Diabetes Association and American College of Cardiology Foundation emphasizing the need for more aggressive goals in controlling lipids to reduce cardiometabolic risk. In particular, the paper focuses for the first time on the need to test for and treat high levels of a protein ...

Statement from Eli Lilly and Company: Response to Connecticut Attorney General News Release

... testing. Patients who develop symptoms of hyperglycemia during treatment should undergo fasting blood glucose testing. Undesirable alterations in lipids have been observed with olanzapine use. Clinical monitoring, including baseline and follow-up lipid evaluations in patients using olanzapine, is ...

FDA Advisory Committee Supports Efficacy and Safety of Zyprexa(R) Long-Acting Injection (LAI) for Schizophrenia Treatment

... testing. Patients who develop symptoms of hyperglycemia during treatment should undergo fasting blood glucose testing. Undesirable alterations in lipids have been observed with olanzapine use. Clinical monitoring, including baseline and follow-up lipid evaluations in patients using olanzapine, is ...

Juvaris BioTherapeutics Announces Cooperative Research and Development Agreement With The Centers for Disease Control and Prevention

... in 2003 to develop an immunotherapeutic product platform for the treatment of infectious diseases and cancers using lipid-DNA complexes. Cationic lipids are formulated with non-coding DNA (plasmid) to create the JuvImmune Immunostimulant, a lipid-DNA complex, which as a single product will have ...